Clinical Trial Update: An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins [Phase 2]

View source ↗

Summary

Phase 2 open-label pilot study of Varisolve PEM for varicose veins completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Varicose Veins

Drugs mentioned

• Varisolve (polidocanol endovenous microfoam (PEM))

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Varicose Veins | Phase 2 | Status: COMPLETED | Results posted: 2014-04-02